Nagarro legt Geschäftszahlen für das 2. Quartal und das 1. Halbjahr 2026 vor und verzeichnet im 2. Quartal bzw. 1. Hj. 2026 Umsatzwachstum von 2,0 % bzw. 4,2 % gegenüber Vorjahr in konstanter Währung

Nagarro meldet im Q2 2026 einen nahezu unveränderten Umsatz von 252,4 Mio. € (vs. 252,0 Mio. €), während das bereinigte EBITDA auf 37,8 Mio. € stieg (+23,9%) und die bereinigte EBITDA-Marge von 12,1% auf 15,0% expandierte. Parallel sank der Gross Profit auf 81,8 Mio. € (Marge 32,4% vs. 33,2%), und das unbereinigte EBITDA fiel auf 27,7 Mio. € (-13,4%) wegen höherer Kosten aktienbasierter Vergütungen. Für das 1. Halbjahr 2026 erhöhte sich das Ergebnis auf 29,8 Mio. € (von 19,6 Mio. €) und der Cashflow aus betrieblicher Tätigkeit ging auf 29,5 Mio. € zurück. Die Hauptversammlung beschloss zudem eine Dividende von 1,00 € je Aktie (12,4 Mio. €; 14,9% des EBIT des Jahres 2025).

Analysis

The setup is more about credibility than acceleration. Revenue being essentially flat while adjusted EBITDA expands tells you management is extracting margin from cost discipline, not from a broad-based demand inflection; that is good for near-term sentiment but rarely enough to justify a sustained multiple rerate in IT services. The market will likely reward the name for showing operating leverage, but longer-duration buyers will need evidence that this is converting into repeatable organic bookings rather than timing noise.

The main second-order risk is that the headline margin improvement is partly a function of non-operating items washing through the P&L, while reported profitability remains sensitive to share-based compensation. In the next 1-3 months, the key catalyst is whether cash collection actually lands as promised; if it does, leverage optics improve and downside gets cushioned, but if it slips, the stock can quickly revert to being viewed as a low-growth, semi-diluted services compounder with limited multiple expansion. The balance sheet is not stressed, so the bear case is not solvency, it is stagnation plus dilution.

Contrarian view: the consensus may be too focused on adjusted EBITDA and too forgiving on top-line quality. In a market that pays up for ACN/EPAM-like consistency, Nagarro likely remains a discount asset until it proves that AI transformation is creating durable mix lift and not just incremental efficiency. The setup is therefore asymmetrically better for a tactical pop than for a structural long unless the upcoming call materially upgrades booking visibility.

Key Decisions for Investors

• Do not chase NGRRF on the headline print; wait for the earnings call and only add on confirmation that organic growth and Q3 cash conversion both improve. Falsifier: if management cannot point to a clear re-acceleration in bookings, treat the stock as range-bound.
• Fade any post-call rally of 5% or more in NGRRF over the next 1-2 weeks with a small short, because the current beat is more margin management than demand inflection. Risk/reward: good if the market overweights adjusted EBITDA, poor if management surprises with strong backlog commentary.
• Relative-value pair: long ACN or EPAM vs short NGRRF for 1-3 months if you want exposure to IT services without paying for a lower-quality growth profile. This captures the premium for durable organic growth and reduces single-name execution risk.
• Set an alert on Q3 operating cash flow and DSO; if DSO moves above 90 days or operating cash flow misses again, exit any long exposure and expect multiple compression. That would be the cleanest falsifier of the bullish interpretation.